NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Myomar Molecular

Myomar Molecular

Private
Halifax, Nova ScotiaHealthcare & Life Scienceshttps://myomarmolecular.ca

Last Round

Seed

May 11, 2026

Total Funding Raised

$4.51M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Myomar Molecular is a biotechnology company that is developing a panel of blood tests to detect and monitor muscle loss (atrophy).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Healthcare Analytics, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS, Government Contracts

AI Layer

Application

Keywords

muscle health testurine testmolecular biomarkersbiomarker analysismuscle health monitoringsarcopeniamuscle metabolismmuscle degenerationGLP-1 muscle lossmenopause muscle healthprecision medicineclinical dashboardat-home testDTC health testhealthcare analytics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Myomar Molecular Comps

Public and private peers based on sector, stage, and business model.

Myomar Molecular comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Myomar Molecular Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 11, 2026
GrantMay 11, 2026
Pre SeedMar 1, 2024
Convertible DebtFeb 7, 2023

Key People

Founding team and executive leadership

Rafaela Andrade

Co-Founder And CEO

Founding Team

Myomar Molecular Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 8, 2026

    Monthly visitors increased 55% MoM, reaching 1.4K.

  • Jan 9, 2026

    Monthly visitors increased 638% MoM.

Myomar Molecular Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Myomar Molecular Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Myomar Molecular's valuation, stock price, and market status.

Firmographic Details

HeadquartersHalifax, Nova Scotia
Employee Range12
Year Founded2020
Last FundingMay 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.